CAAS Capital Management’s Orphazyme A/S ORPH Stock Holding History

CAAS Capital Management’s Portfolio ORPH Stock Details ORPH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-20,156	Closed	-$169K	–	1456
2021 Q1	$169K	Sell	20,156 -4,844	-19%	-$59.6K	﹤0.01%	1056
2020 Q4	$268K	Hold	25,000	–	–	﹤0.01%	740
2020 Q3	$258K	Buy	+25,000	New	+$251K	0.01%	424

Other funds holding ORPH

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return

BAM

Blueshift Asset Management Red Bank, New Jersey $432M AUM 13.14% 1-Year Est. Return

Simplex Trading Chicago, Illinois $171B AUM 85% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $304B AUM 35.64% 1-Year Est. Return

Cutler Group San Francisco, California $307M AUM 45.11% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

CAAS Capital Management's ORPH Position: Q2 2021 in Review

CAAS Capital Management sold out of Orphazyme A/S (ORPH) in Q2 2021, closing a stake of 20,156 shares — an estimated $169K sold.

CAAS Capital Management first reported a position in ORPH in Q3 2020 and held it in 3 quarters. The position peaked at $268K in Q4 2020. 20 funds tracked by Wall St. Rank hold ORPH as of Q2 2021.

CAAS Capital Management reported no remaining Orphazyme A/S position as of Q2 2021 after selling out during the quarter.
CAAS Capital Management sold 20,156 Orphazyme A/S shares in Q2 2021, an estimated $169K.
CAAS Capital Management first reported a position in Orphazyme A/S in Q3 2020 and held it in 3 quarters.
CAAS Capital Management's Orphazyme A/S position peaked at $268K in Q4 2020.
20 funds tracked by Wall St. Rank held Orphazyme A/S as of Q2 2021.

Based on CAAS Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.